LIMN NASDAQ
Liminatus Pharma, Inc. Class A Common Stock
1W: -7.1%
1M: +1.6%
3M: -45.3%
YTD: -87.8%
1Y: -95.5%
$3.90
+0.15 (+4.00%)
Weekly Expected Move ±10.0%
$3
$4
$4
$4
$5
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (13)
Liminatus Pharma regains Nasdaq compliance
Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy
Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's Intraday Session
Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline
Liminatus Pharma Is Trending Overnight — Here's Why LIMN Stock Surged Over 79% In After-Hours Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Thursday's Intraday Session
Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering